Cite
HARVARD Citation
Smolen, J. et al. (2013). THU0202 Five-Year Safety and Efficacy of Golimumab in Patients with Active Rheumatoid Arthritis Despite Previous Anti-Tumor Necrosis Factor Therapy: Final Study Results of the Phase 3, Randomized, Placebo-Controlled Go-After Trial. Annals of the rheumatic diseases. p. A232. [Online].